Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?

Kenneth Blum, Thomas J.H. Chen, John Bailey, Abdalla Bowirrat, John Femino, Amanda L.C. Chen, Thomas Simpatico, Siobhan Morse, John Giordano, Uma Damle, Mallory Kerner, Eric R. Braverman, Frank Fornari, B. William Downs, Cynthia Rector, Debmayla Barh, Marlene Oscar-Berman

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Opiate addiction is associated with many adverse health and social harms, fatal overdose, infectious disease transmission, elevated health care costs, public disorder, and crime. Although community-based addiction treatment programs continue to reduce the harms of opiate addiction with narcotic substitution therapy such as methadone maintenance, there remains a need to find a substance that not only blocks opiate-type receptors (mu, delta, etc.) but also provides agonistic activity; hence, the impetus arose for the development of a combination of narcotic antago-nism and mu receptor agonist therapy. After three decades of extensive research, the federal Drug Abuse Treatment Act 2000 (DATA) opened a window of opportunity for patients with addiction disorders by providing increased access to options for treatment. DATA allows physicians who complete a brief specialty-training course to become certified to prescribe buprenorphine and buprenorphine/ naloxone (Subutex, Suboxone) for treatment of patients with opioid dependence. Clinical studies indicate that buprenorphine maintenance is as effective as methadone maintenance in retaining patients in substance abuse treatment and in reducing illicit opioid use. With that stated, we must consider the long-term benefits or potential toxicity attributed to Subutex or Suboxone. We describe a mechanism whereby chronic blockade of opiate receptors, in spite of only partial opiate agonist action, may ultimately block dopaminergic activity causing anti-reward and relapse potential. While the direct comparison is not as yet available, toxicity to buprenorphine can be found in the scientific literature. In considering our cautionary note in this commentary, we are cognizant that, to date, this is what we have available, and until such a time when the real magic bullet is discovered, we will have to endure. However, more than anything else this commentary should at least encourage the development of thoughtful new strategies to target the specific brain regions responsible for relapse prevention.

Original languageEnglish
Pages (from-to)250-268
Number of pages19
JournalMolecular Neurobiology
Volume44
Issue number3
DOIs
StatePublished - Dec 2011
Externally publishedYes

Keywords

  • Buprenorphine
  • Dopamine
  • Naloxone
  • Opioid dependence
  • Relapse
  • Suboxone
  • Subutex thtrthn

Fingerprint

Dive into the research topics of 'Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?'. Together they form a unique fingerprint.

Cite this